Allergy Therapeutics PLC Total Voting Rights (2980V)

TIDMAGY

RNS Number : 2980V

Allergy Therapeutics PLC

01 December 2023

Al l er gy Therapeu tics p lc

(" A l l ergy Ther apeut ics", the "Group" or "C o mpany ")

Total Voting Rights

1 December 2023 Allergy Therapeutics plc (AIM: AGY) announces that pursuant to its block admission facility, it has recently issued 4,928,544 ordinary shares of 0.1 pence each in the capital of the company ("Ordinary Shares") in satisfaction of the exercise of share options. The new Ordinary Shares rank pari passu with the Company's existing shares.

In accordance with DTR 5.6.1 of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, as at 30 November 2023, the Company has 4,763,874,771 Ordinary Shares in issue. There are no shares held in treasury. The total number of voting rights in the Company is therefore 4,763,874,771.

The above figure of 4,763,874,771 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information, please contact:

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

[phone]

Panmure Gordon (Rule 3 Adviser, Nominated Adviser and Broker)

Emma Earl, Mark Rogers, Freddy Crossley, Corporate Finance

Rupert Dearden, Corporate Broking

[phone]

ICR Consilium

Mary-Jane Elliott / David Daley / Davide Salvi

[phone]

[e-mail]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. For more information, please see www.allergytherapeutics.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVREAPFEDFKDFFA

(END) Dow Jones Newswires

December 01, 2023 02:00 ET (07:00 GMT)